A single-centre experience of intravenous thrombolysis for stroke in COVID-19 patients.
Davide SangalliValeria PoloniaDaniele ColomboVittorio ManteroMarco FilizzoloChiara ScaccabarozziAndrea SalmaggiPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2020)
The sudden worldwide outbreak of Coronavirus Disease 2019 (COVID-19) has certainly provided new challenges in the management of acute ischaemic stroke, and the risk-benefit ratio of intravenous thrombolysis in COVID-19 positive patients is not well known. We describe four COVID-19 patients treated with intravenous thrombolysis for acute ischaemic stroke. Although rt-PA administration is the main therapeutic strategy, our patients experienced unpredictable complications and showed atypical features: the overall mortality was very high. In conclusion, in this article, we provide information about these cases and discuss the possible explanation behind this trend.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- pulmonary embolism
- chronic kidney disease
- newly diagnosed
- liver failure
- high dose
- peritoneal dialysis
- prognostic factors
- atrial fibrillation
- risk factors
- cardiovascular disease
- respiratory syndrome coronavirus
- coronary artery disease
- healthcare
- cardiovascular events
- drug induced